Using Research and Expert Consultations to Develop Educational Materials for a National HIV Vaccine Research Initiative

Research on willingness to participate in HIV vaccine trials is important in preparations for HIV vaccine research, but there are few data from sub-Saharan Africa. We interviewed 198 individuals in a peri-urban South African community immediately after enrolment into an HIV vaccine preparedness study on their willingness to participate in hypothetical vaccine trials. Overall 23% of participants ( n = 46) said that they would be willing to participate in an HIV vaccine trial. Willingness was associated with increasing age, male gender, and increasing knowledge about vaccines generally and HIV vaccines specifically. In multivariate analysis, a 1-unit increase in HIV vaccine knowledge score was associated with a 10-fold increase in willingness to participate (adjusted odds ratio, 10.72, 95% confidence intervals: 4.40–26.12). These results suggest that while willingness to participate in HIV vaccine trials is relatively low in this setting, educational campaigns may have a substantial impact on individuals' willingness to participate in research.

Download Full-text

A (prime) boost for HIV vaccine research?

The Lancet ◽

10.1016/s0140-6736(09)61720-7 ◽

2009 ◽

Vol 374 (9696) ◽

pp. 1119 ◽

Cited By ~ 1

Author(s):

The Lancet

Keyword(s):

Hiv Vaccine ◽

Vaccine Research

Download Full-text

What Has 30 Years of HIV Vaccine Research Taught Us?

Vaccines ◽

10.3390/vaccines1040513 ◽

2013 ◽

Vol 1 (4) ◽

pp. 513-526 ◽

Cited By ~ 19

Author(s):

José Esparza

Keyword(s):

Hiv Vaccine ◽

Vaccine Research

Download Full-text

Editorial: Paradigm Changes Are Required in HIV Vaccine Research

HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design ◽

10.1007/978-3-030-32459-9_16 ◽

2019 ◽

pp. 199-203

Author(s):

Marc H V Van Regenmortel

Keyword(s):

Hiv Vaccine ◽

Vaccine Research

Download Full-text

Incentives and Disincentives to Participate in Prophylactic HIV Vaccine Research

Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ◽

10.1097/00042560-199505010-00006 ◽

1995 ◽

Vol 9 (1) ◽

pp. 36???42 ◽

Cited By ~ 18

Author(s):

Richard A. Jenkins ◽

Lydia R. Temoshok ◽

Kittichatr Virochsiri

Keyword(s):

Hiv Vaccine ◽

Vaccine Research

Download Full-text

V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers

Animals ◽

10.3390/ani9080526 ◽

2019 ◽

Vol 9 (8) ◽

pp. 526 ◽

Cited By ~ 6

Author(s):

Duerr ◽

Gorny

Keyword(s):

Vaccine Efficacy ◽

Natural Infection ◽

Vaccine Trial ◽

Clinical Findings ◽

Hiv Vaccine ◽

Model Systems ◽

Potential Contribution ◽

Vaccine Research ◽

Specific Antibodies ◽

Hiv 1

Most human immunodeficiency virus (HIV) vaccine trials have lacked efficacy and empirical vaccine lead targets are scarce. Thus far, the only independent correlate of reduced risk of HIV-1 acquisition in humans is elevated levels of V2-specific antibodies identified in the modestly protective RV144 vaccine trial. Ten years after RV144, human and non-human primate vaccine studies have reassessed the potential contribution of V2-specific antibodies to vaccine efficacy. In addition, studies of natural HIV-1 infection in humans have provided insight into the development of V1V2-directed antibody responses and their impact on clinical parameters and disease progression. Functionally diverse anti-V2 monoclonal antibodies were isolated and their structurally distinct V2 epitope regions characterized. After RV144, a plethora of research studies were performed using different model systems, immunogens, protocols, and challenge viruses. These diverse studies failed to provide a clear picture regarding the contribution of V2 antibodies to vaccine efficacy. Here, we summarize the biological functions and clinical findings associated with V2-specific antibodies and discuss their impact on HIV vaccine research.

Download Full-text